| In Vitro |
SRT 2183 (1-10 μM; 24-72 hours) inhibits the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner[2]. SRT 2183 (5-10 μM in Reh cells; 10 μM in Ly3 cells; 24 hours) induces expression of DNA-damage response genes associated with accumulation of phospho-H2A.X levels[2]. SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival[3]. Cell Proliferation Assay[2] Cell Line: Reh cells, Nalm-6 cells (pre-B acute lymphoblastic leukemia (ALL) cell lines) Concentration: 1 μM, 5 μM, 10 μM Incubation Time: 24 hours, 48 hours, 72 hours Result: Inhibited the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. The IC50 (median inhibition concentration) values for SRT 2183-mediated inhibition of proliferation at 48 h are approximately 8.7 μM for Reh cells and approximately 3.2 μM for Nalm-6 cells. Western Blot Analysis[2] Cell Line: Reh cells, Ly3 cells Concentration: 5μM and 10μM (Reh cells); 10μM (Ly3 cells) Incubation Time: 24 hours Result: Induced accumulation of phospho-H2A.X in Reh as well as in Ly3 cells.
|
